Place of GLP-1 receptor antagonists and SGLT-2 inhibitors in modern therapy of type 2 diabetes mellitus


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article discusses modern approaches to the treatment of patients with type 2 diabetes mellitus (DM2) using non-pharmaco-logical and medicinal methods of treatment. The problem of treating diabetes in the modern world does not lose its relevance. Recommendations for the initiation and intensification of therapy for DM2 patients are updated annually. The main stages of the use of hypoglycemic drugs are presented.

Full Text

Restricted Access

About the authors

M. B Antsiferov

Endocrinological Dispensary of the Moscow Heathcare Department

Email: antsiferov@rambler.ru
Dr. Sci. (Med.), Professor, President Moscow, Russia

O. M Koteshkova

Endocrinological Dispensary of the Moscow Heathcare Department

Moscow, Russia

O. V Dukhareva

Endocrinological Dispensary of the Moscow Heathcare Department

Moscow, Russia

N. A Demidov

Hospital in Moskovsky town of the Moscow Healthcare Department

Moscow, Russia

M. S Novikova

Endocrinological Dispensary of the Moscow Heathcare Department

Moscow, Russia

References

  1. www.diabetesatlas.org. Facts & figures (idf.org). URL: https://www.idf.org/aboutdiabetes/what-is-diabetes/facts-figures.html
  2. Davies M.J., Arora V.R., Vanita R., et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetol. 2022;65,1925-66. doi: 10.1007/s00125-022-05787-2.
  3. Breslin M., Mullan R.J., Montori V.M. The design of a decision aid about diabetes medications for use during the consultation with patients with type 2 diabetes. Patient Educ Couns. 2008;73:465-72. doi: 10.1016/j.pec.2008.07.024.
  4. Lingvay I., Sumithran P., Cohen R.V., le Roux C.W. Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. Lancet. 2022;399: 394-405. doi: 10.1016/S0140-6736(21)01919-X.
  5. Riddle M.C., Cefalu W.T., Evans P.H., et al. Consensus report: definition and interpretation of remission in type 2 diabetes. Diab Care. 2021;44:2438-44. doi: 10.2337/dci21-0034.
  6. Schwingshackl L., Chaimani A., Hoffmann G, et al.Network meta-analysis on the comparative efficacy of different dietary approaches on glycaemic control in patients with type 2 diabetes mellitus. Eur J Epidemiol. 2018;33:157-70. doi: 10.1007/s10654-017-0352-x.
  7. Estruch R, Ros E., Salas-Salvado J., et al. PREDIMED Study Investigators. Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts. N Engl J Med. 2018;378:e3476,77. doi: 10.1056/NEJMoa1800389.
  8. Lean M.E., Leslie W.S., Barnes A.C., etal. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet. 2018;391:541-51. doi: 10.1016/S0140-6736(17)33 1 02-1.
  9. Lean M.E.J., Leslie W.S., Barnes A.C., et al. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. Lancet. Diab Endocrinol. 2019;7:344-55. Doi: 10.1016/ S2213-8587(19)30068-3.
  10. Delevatti R.S., Bracht C.G., Lisboa S.D.C., et al. The role of aerobic training variables progression on glycemic control of patients with type 2 diabetes: a systematic review with meta-analysis. Sports Med Open. 2019;5:22. doi: 10.1186/s40798-019-0194-z.
  11. Lalau J.D., Kajbaf F., Bennis Y., et al. Metformin treatment in patients with type 2 diabetes and chronic kidney disease stages 3A, 3B, or 4. Diab Care. 2018;41:547-53. doi: 10.2337/dc17-2231.
  12. Nauck M.A., Quast D.R., Wefers J., Meier J.J. GLP-1 receptor agonists in the treatment of type 2 diabetes-state-of-the-art. Mol Metab. 2021;46:101102. Doi: 10.1016/j. molmet.2020.101102.
  13. Frias J.P., Bonora E., Nevarez Ruiz L., et al. Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg versus dulaglutide 1.5 mg in metformin-treated patients with type 2 diabetes in a randomized controlled trial (AWARD-11). Diab Care. 2021;44:765-73. doi: 10.2337/dc20-1473.
  14. Frias J.P, Auerbach P, Bajaj H.S., et al. Efficacy and safety of once-weekly semaglutide 2*0 mg versus 1*0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial. Lancet. Diab. Endocrinol. 2021;9:563-74. doi: 10.1016/S2213-8587(21) 00174-1.
  15. Bethel M.A., Diaz R, Castellana N., et al. HbA1c change and diabetic retinopathy during GLP-1 receptor agonist cardiovascular outcome trials: a meta-analysis and meta-regression. Diab Care. 2021;44(1):290-96. doi: 10.2337/dc20-1815.
  16. Heerspink H.J.L., Stefansson B.V., Correa-Rotter R., et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436-46. doi: 10.1056/NEJMoa2024816.
  17. Kosiborod M.N., Esterline R., Furtado R.H.M., et al. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. Diab Endocrinol. 2021;9:586-94. doi: 10.1016/S2213- 8587(21)00180-7.
  18. Cannon C.P, Pratley R., Dagogo-Jack S., et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020;383:1425-35. doi: 10.1056/NEJMoa2004967.
  19. Heerspink H.J.L., Jongs N., Chertow G.M., et al. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. Randomized Controlled Trial. Lancet. Diab Endocrinol. 2021;9(11):743-54. Doi: 10.1016/ S2213-8587(21)00242-4.
  20. Packer M., Anker S.D., Butler J., et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383:1413-24. doi: 10.1056/NEJMoa2022190.
  21. Shaman A.M., Bain S.C., Bakris G.L., et al. Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER. Circulation. 2022;145:575-85. Doi: 10.1161/ CIRCULATIONAHA.121.055459.
  22. Sattar N., Lee M.M.Y., Kristensen S.L., et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and metaanalysis of randomised trials. Lancet. Diab Endocrinol. 2021;9:653-62. Doi: 0.1016/ S2213-8587(21)00203-5.
  23. Neuen B.L., Young T, Heerspink H.J.L., et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet. Diab Endocrinol. 2019;7:845-54. Doi: 10.1016/ S2213-8587(19)30256-6.
  24. Neuen B.L., Arnott C., Perkovic V., et al. Sodium-glucose co-transporter-2 inhibitors with and without metformin: a meta-analysis of cardiovascular, kidney and mortality outcomes. Diab Obes Metab. 2021;23:382-90. doi: 10.1111/dom.14226.
  25. Tsapas A., Karagiannis T., Avgerinos I., et al. GLP-1 receptor agonists for cardiovascular outcomes with and without metformin. A systematic review and meta-analysis of cardiovascular outcomes trials. Diab Res Clin Pract. 2021;177:108921. doi: 10.1016/j.diabres.2021.108921.
  26. Lavalle-Cobo A., Masson W., Lobo M., et al. Glucagon-like peptide-1 receptor agonists and cardioprotective benefit in patients with type 2 diabetes without baseline metformin: a systematic review and update meta-analysis. High Blood Press Cardiovasc Prev. 2021;28:605-12. doi: 10.1007/s40292-021-00479-1.
  27. Palmer S.C., Tendal B., Mustafa R.A., et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2021;372:m45 73. doi: 10.1136/bmj.m4573.
  28. Lin D.S.H., Lee J.K., Hung C.S., Chen W.J. The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials. Diabetol. 2021;64:2676-86. doi: 10.1007/s00125-021-05529-w.
  29. Patorno E., Htoo P.T., Glynn R.J., et al. Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease. Ann Intern Med. 2021;174:1528-41. doi: 10.7326/M21-0893.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies